Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Rabies Ad Cited By FDA For Lack Of Risk Information

This article was originally published in The Pink Sheet Daily

Executive Summary

A poster for Imovax and Imogam should be discontinued because it does not mention adverse events, CBER says. The ad also implies that other products are not available, the agency’s letter states.

You may also be interested in...



Aventis Typhoid Promotion Cited For Effectiveness Claim

A Typhim Vi flashcard suggests the vaccine protects against typhoid without the need for reimmunization, an FDA letter states. The agency also objects to a comparative claim with another typhoid vaccine.

Aventis Typhoid Promotion Cited For Effectiveness Claim

A Typhim Vi flashcard suggests the vaccine protects against typhoid without the need for reimmunization, an FDA letter states. The agency also objects to a comparative claim with another typhoid vaccine.

Aventis Recalls Rabies Vaccine

Aventis Pasteur is recalling four lots of its rabies vaccine Imovax following discovery of a non-inactivated virus.

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel